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Cytomegalovirus Myocarditis Required Extracorporeal 
Membrane Oxygenation Support Followed by 
Ganciclovir Treatment in Infant
Bong Jun Kim, M.D.1, Jo Won Jung, M.D.2, Yu Rim Shin, M.D.1, Han Ki Park, M.D.1, 
Young Hwan Park, M.D.1, Hong Ju Shin, M.D.1,3
A 7-month-old girl with no medical history was treated with mechanical circulatory support due to myocarditis. Her 
cardiac contractility did not improve despite more than one week of extracorporeal membrane oxygenation treatment. 
Thus, we planned a heart transplant. However, a high level of cytomegalovirus was found in blood laboratory re-
sults by quantitative polymerase chain reaction. The patient’s heart contractility recovered to normal range four 
days after ganciclovir treatment. She was discharged with slightly decreased cardiac contractility with a left ven-
tricular ejection fraction of 45%.
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CASE REPORT
A 7-month-old girl was referred to Severance Cardiovascu-
lar Hospital for suspected myocarditis. Her medical and fami-
lial history was unremarkable. However, fever and lethargic 
symptoms had developed five days before presentation. Her 
body weight was 7.6 kg. A chest X-ray showed cardiomegaly 
with a cardiothoracic ratio of 0.67 (Fig. 1) and electro-
cardiography revealed normal sinus rhythm with a heart rate 
of 158/min. Echocardiogram revealed decreased left ven-
tricular (LV) ejection fraction (LVEF) of 10% and an en-
larged left ventricle. An initial laboratory test revealed ele-
vated levels of cardiac enzymes (creatine kinase–myocardial 
band 10.4 ng/mL, troponin-T 0.289 ng/mL). Intravenous use 
of inotropics, including dopamine, milrinone, and epinephrine, 
were infused. However, metabolic acidosis developed and a 
follow-up echocardiogram showed additionally decreased 
LVEF of 3% to 5%. Therefore, we decided to apply ex-
tracorporeal membrane oxygenation (ECMO) support. Arterial 
cannulation was performed via the right carotid artery with a 
10 French percutaneous arterial cannula (RMI; Edwards 
Lifesciences, Irvine, CA, USA) and a 14 French percutaneous 
venous cannula (RMI, Edwards Lifesciences) was placed in 
the right internal jugular vein (Fig. 2). Capiox EBS-PMP 
(Terumo Ltd., Tokyo, Japan) was used to support circulatory 
function. ECMO flow was maintained between 700 and 800 
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Fig. 1. Chest X-ray showed cardiomegaly.
Fig. 2. Chest X-ray showed extracorporeal membrane oxygenation 
support via right neck vessel.
Fig. 3. Chest X-ray showed left atrial venting cannula insertion 
through right femoral vein.
mL/min. The metabolic acidosis improved rapidly after 
ECMO; however, the sputum took on a pinkish and watery 
character the next day. Severe left atrial (LA) enlargement 
was observed in the echocardiogram; thus emergent atrial 
septostomy with a 8.5 Fr LA venting cannula (Mullins 
sheath; Cook Inc., Somerset, NJ, USA) insertion through the 
right femoral vein was performed percutaneously (Fig. 3). 
Decreased LA enlargement and LV size were observed on 
echocardiography with intact septostomy flow. Inotropic sup-
port was kept to maintain cardiac contraction and intravenous 
immunoglobulin (2 g/kg) was also infused as immunomodu-
latory therapy. Three days after ECMO insertion, however, 
LV contraction was not recovered with LVEF of 15%. Unlike 
the myocarditis course in other cases, recovery was slow de-
spite more than one week of mechanical circulatory support. 
Because there was no improvement of LVEF despite a long 
period of mechanical circulatory support, heart transplantation 
was considered for a possible dilated cardiomyopathy. 
Microbiological results were reported, but common causes of 
myocarditis such as coxsackie B, adenovirus, and parvovirus 
were negative. Instead, high level of cytomegalovirus (CMV) 
via quantitative polymerase chain reaction (PCR) was re-
ported in the blood (720 copies/mL, normal range ＜250 cop-
ies/mL). CMV antibody immunoglobulin G (IgG) titer was 
positive (66 AU/mL, normal range ＜4 AU/mL); however, 
CMV immunoglobulin M titer was equivocal (0.89 AU/mL, 
normal range ＜0.7 AU/mL). Preoperative examination for 
transplantation that included evaluation for congenital im-
munodeficiency and viral antibody was not remarkable. 
During the mechanical circulatory support of almost two 
weeks, there was little improvement of heart contractility. 
Because of deteriorating oxygenator function and worsening 
hyperbilirubinemia, we decide to stop ECMO with maximal 
inotropic support. The duration of ECMO support was 324 
CMV Myocarditis Treated with ECMO and Ganciclovir
− 201 −
hours. During follow-up of whole blood laboratory results, 
CMV titer revealed a higher level than in a previous result 
(6,250 copies/mL). Because the CMV titer increased nine 
times within two weeks and there was no evidence of other 
disease, we decided to start intravenous ganciclovir at 2.5 mg/kg 
twice a day. Two days after ganciclovir treatment, LVEF im-
proved to 35%. Heart contractility recovered to normal range 
four days after. Thus, we continued to use ganciclovir treat-
ments for two weeks in total. After two weeks of treatment, 
CMV PCR titer decreased to normal range and LVEF recov-
ered to 46%. However, one week after ganciclovir stopped, 
follow-up CMV PCR titer in the urine was still high (＞
1,150 copies/mL), so another two weeks of ganciclovir treat-
ment was applied and CMV PCR titer returned to normal. 
Even though the hospital course of the patient was continued 
over three months due to renal failure and ventilator-asso-
ciated pneumonia, a low CMV titer and recovered heart func-
tion remained until discharge. The duration of hospital stay 
was 109 days. Follow-up echocardiography 14 months later 
showed recovered cardiac contractility with LVEF of 64% 
and decreased heart size in chest radiography.
DISCUSSION
Myocarditis is defined as an inflammation of the heart 
muscle, and it can lead to myocardial dysfunction. Viral in-
fections such as coxsackie B enterovirus, adenovirus, and par-
vovirus B19 are common causes of myocarditis. CMV in-
fection is common among many people, regardless of age or 
race, but serious disease may occur in immunocompromised 
patients such as transplant recipients or congenitally infected 
newborns [1]. However, CMV myocarditis is rare even in im-
munocompromised patients [2.3], and there are just a few re-
ports about CMV myocarditis in immunocompetent patients 
[1,4,5]. The patient had no remarkable illness before admi-
ssion. Her physical and neurological development and the re-
sults of laboratory investigation for primary immunode-
ficiencies were normal. Symptomatic CMV infections rarely 
occur in immunocompetent patients like her. However, ne-
glecting the potential of CMV myocarditis led to a mis-
diagnosis of dilated cardiomyopathy.
In this case, CMV myocarditis was proven by quantitative 
PCR in blood and urine. CMV antibody IgG was also pos-
itive in this patient, but most of the general population in 
Korea has CMV antibody IgG. A positive result may reflect 
passive transmission of a maternal antibody [6]. The PCR re-
sults of other known causes of viral myocarditis were all 
negative and a bacterial culture study was also negative. 
Though we did not perform myocardium biopsy, the negative 
result from the other study was enough to diagnose CMV 
myocarditis. In contrast to other types of viral myocarditis, 
the use of an antiviral agent is a feasible treatment choice for 
CMV myocarditis.
If the opportunity to recover LVEF was lost due to a delay 
in ganciclovir treatment, the only treatment option for the pa-
tient would have been heart transplantation, and heart trans-
plantation for this patient would have been an inappropriate 
treatment.
Mechanical circulatory support is necessary for both ful-
minant myocarditis and severe dilated cardiomyopathy [2]. 
Temporary mechanical circulatory support can buy time for 
myocardial recovery or bridge to transplantation [3]. In this 
case, initial cardiac function was impaired and insufficient for 
maintaining blood pressure; therefore, ECMO was applied. 
This enabled us to buy time for exact diagnosis and allowed 
for slight myocardial recovery.
Ganciclovir has a dramatic effect on CMV myocarditis 
[1,4,7]. Improvement of LVEF was achieved in two days, 
and it reached normal values within five days of therapy. 
Though there was no biopsy result, clinical and chronological 
links between administrations of ganciclovir and cardiac func-
tion recovery suggested the effectiveness of this medicine in 
CMV myocarditis. When we encounter patients with my-
ocarditis, we should consider CMV as a possible cause, and 
tests for CMV infection should be performed. If the result 
suggests CMV myocarditis, an antiviral agent like ganciclovir 
should be tried for treatment of the underlying disease.
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